Iovance Biotherapeutics (IOVA) Cash & Current Investments (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Cash & Current Investments of $313.4 million for Q1 2026, down 12.86% year-over-year from $359.7 million in Q1 2025, and up 5.54% quarter-over-quarter from $297.0 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Cash & Current Investments (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Cash & Current Investments for 16 consecutive years, with $313.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 12.86% year-over-year to $313.4 million; the TTM figure through Mar 2026 stood at $313.4 million (down 12.86% YoY), while the FY2025 annual figure was $297.0 million, down 8.28% from the prior year.
- Cash & Current Investments grew to $313.4 million in Q1 2026 per IOVA's latest filing, from $297.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $626.3 million in Q1 2023 and bottomed at $164.2 million in Q3 2024.
- Historically, Cash & Current Investments has averaged $347.2 million across 5 years, with a median of $323.8 million in 2024.
- Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 54.56% — and 2025, when it soared 83.21%.
- Iovance Biotherapeutics' Cash & Current Investments stood at $471.8 million in 2022, then plunged by 40.69% to $279.9 million in 2023, then climbed by 15.69% to $323.8 million in 2024, then decreased by 8.28% to $297.0 million in 2025, then rose by 5.54% to $313.4 million in 2026.
- Business Quant data shows IOVA's Cash & Current Investments at $313.4 million in Q1 2026, $297.0 million in Q4 2025, and $300.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 297.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 297.71 Mn |
| Mar 31, 2026 | 313.44 Mn |
| Dec 31, 2025 | 296.98 Mn |
| Sep 30, 2025 | 300.80 Mn |
| Jun 30, 2025 | 301.20 Mn |
| Mar 31, 2025 | 359.71 Mn |
| Dec 31, 2024 | 323.78 Mn |
| Sep 30, 2024 | 164.19 Mn |
| Jun 30, 2024 | 228.68 Mn |
| Mar 31, 2024 | 356.20 Mn |
| Dec 31, 2023 | 279.87 Mn |
| Sep 30, 2023 | 361.35 Mn |
| Jun 30, 2023 | 250.90 Mn |
| Mar 31, 2023 | 626.29 Mn |
| Dec 31, 2022 | 471.85 Mn |
| Sep 30, 2022 | 360.17 Mn |
| Jun 30, 2022 | 424.48 Mn |
| Mar 31, 2022 | 482.16 Mn |
| Dec 31, 2021 | 504.41 Mn |
| Sep 30, 2021 | 576.49 Mn |